Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Aragen will provide IDD services to support FAR Biotech's AI-driven, quantum biomodelling approach.
May 30, 2023
By: Anthony Vecchione
Aragen Life Sciences (Aragen), a contract research and development organization (CRO), and FAR Biotech (FAR), a U.S.-based, AI-driven, computational drug discovery company, have collaborated to advance preclinical programs in neurodegeneration. As part of the collaboration, Aragen will deploy its discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration. “We look forward to initiating our collaboration with FAR Biotech to advance its pipeline of therapeutic candidates,” said Ramesh Subramanian, chief commercial officer, Aragen. “Aragen has developed strong capabilities in providing integrated drug discovery (IDD) solutions to its customers to accelerate their discovery programs and this collaboration marks an inflection point for our IDD vertical.” Simon Haydar, senior vice president & head of integrated drug discovery, Aragen, said, “We are encouraged by the in-silico molecules we’ve seen coming out of FAR Biotech over the past several months and look forward to helping them advance their neurodegeneration program. We are confident that the outcome will be novel therapeutic candidates for a high-impact target that has proven hard to drug.” Martin Martinov, CEO, FAR Biotech, said, “A key therapeutic area for FAR Biotech is neurodegeneration, where we believe our computational approach can deliver structurally diverse, novel molecules that move us closer to overcoming Alzheimer’s, Parkinson’s and other related diseases that have thus far proven intractable. We are very pleased to be collaborating with Aragen – who we regard as a highly complementary expert partner that can help to accelerate our neurodegeneration program.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !